Despite all restrictions and taking into account the COVID regulations, CEO Dr. Bolzern did not miss the opportunity to attend the celebration of the 25th anniversary of the PharmaZell Group site Chennai (India).
CEO Dr. Oliver Bolzern visited the Visakhapatnam site in February. He appreciated the various measures and efforts taken during COVID pandemic which has helped to restrict any potential disturbance in the operations.
We are pleased to announce that the activities on synthetic CBD at our Farmabios site are progressing smoothly. The API is produced at a commercial batch size using a THC-free route, allowing us to satisfy high customer demands. As extension to the existing EU- and US-DMF for our pharmaceutical grade CBD, a Novel Food dossier
FarmaBios successfully completed the certification process in accordance with the ISO 45001:2018 standards. The new certificate is the last achievement of the list together with ISO 9001:2015 and ISO 14001:2015. With this certificate valid until 28th July 2023, FarmaBios presents objective evidence for the commitment to provide high quality and to works on continuous improvement
PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running. Up to now, the PharmaZell Group has been able to limit the impact of the Corona Virus outbreak (COVID-19) to the largest extent. Despite the fact that
During this critical and challenging period, Farmabios SpA states that our activities are regularly proceeding. We are conscious of the role and duty in delivering APIs, and our active part in the health system. We are doing our utmost to preserve our partners’ service continuously through our the work of our head quarter and manufacturing
The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint is an international asset management firm with over €20 billion of assets under management. Commenting on the transaction, PharmaZell CEO Dr. Oliver Bolzern, said: “We
As part of an ongoing investment program to enhance PharmaZell Group’s production output, we have initiated the construction of a brand new large steroid building and a new warehouse on the Farmabios premises in Gropello Cairoli (Italy). Construction work began in Dec 2019, a symbolic ground breaking ceremony is planned for Mar 2020. The investment
We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].